JACC. Heart failure 2025; AOP:10.1016/j.jchf.2025.102766 |
García-Pavía, Pablo et al.
Recognizing the lack of disease monitoring recommendations in transthyretin amyloid cardiomyopathy (ATTR-CM), international experts convened in 2021 to propose criteria for monitoring disease progression....
Amyloid 2025; 32(1): 39-45 |
Yusuke
Mochizuki
a
et al.
Diarrhoea is one of the most serious complications in hereditary ATTR (ATTRv) amyloidosis. However, its precise pathomechanism remains unknown. The present study investigated the involvement of bile acid...
Amyloid 2025; 32(1): 72-80 |
Brian C.
Netzel
a
et al.
Cardiac AL and ATTR are potentially fatal cardiomyopathies. Current therapies do not address mechanisms of tissue dysfunction because these remain unknown. Our prior work focused on the amyloid plaque...
By requesting access to the "ATTR Expert" service, I agree that GNM Healthcare Consulting France SAS may use the data acquired during my access request to provide me with twice per month
information related to its services in accordance with the
Privacy Policy.
You have the right to access, rectify and delete your data, which you can exercise by sending your request to
dpo@gnmhealthcare.com.
You can exercise your right to object by requesting the deletion of your data at any time by clicking on the "Delete my data" link.
